Compare STAA & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STAA | PTGX |
|---|---|---|
| Founded | 1982 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 9.3B |
| IPO Year | 1995 | 2016 |
| Metric | STAA | PTGX |
|---|---|---|
| Price | $20.64 | $142.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $22.81 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 803.8K | 526.9K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.26 | ★ 2.35 |
| Revenue | ★ $239,442,000.00 | N/A |
| Revenue This Year | $30.82 | $874.25 |
| Revenue Next Year | $8.41 | N/A |
| P/E Ratio | $73.38 | ★ $58.44 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.59 | $62.24 |
| 52 Week High | $35.87 | $160.81 |
| Indicator | STAA | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 40.21 | 46.76 |
| Support Level | $19.82 | $141.95 |
| Resistance Level | $26.21 | $151.24 |
| Average True Range (ATR) | 1.05 | 5.11 |
| MACD | -0.22 | -0.89 |
| Stochastic Oscillator | 30.25 | 48.37 |
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.